LaVoieHealthScience Announces New PR Clients to its Roster

BOSTON, MA – March 23, 2017LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced it has signed new clients to its public relations client roster including BioAxone BioSciences, Inc.,

 “Our passion is to represent true innovators in the health and science fields,” said Donna L. LaVoie, President and CEO, LaVoieHealthScience.  “Our client companies are led by scientific and business visionaries who are shaping the way patients will be treated and making difference in healthcare delivery. We are delighted to expand our reach in biotechnology, medical device, and medical technology.” 

LaVoieHealthScience is leading a full array of integrated communications for these new clients including LHS Immersion®, The LHS Fifteen Slide Presentation®,  investor and corporate communications, investor and business development access, local and national media relations, digital and content development, thought leadership as well as social engagement programs.  The companies’ expertise includes:

  • BioAxone BioSciences, Cambridge, MA is committed to applying a deep understanding of  axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or neurovascular disorder.
  • MicroPort Orthopedics, Burlington, MA,  is a medical device company that develops and manufactures knee and hip implants designed to help patients achieve full function faster. 
  • Major global pharmaceutical company, Cambridge MA, is exploring cutting-edge science and technology opportunities with relevance for dermatology.

About LaVoieHealthScience
LaVoieHealthScience partners with leading life science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received 28 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients.  In addition to clients listed above, LaVoieHealthScience represents leaders such as Cydan Development, Imara, NewLink Genetics, Biotechnology Innovation Organization, Newron Pharmaceuticals, Origenis, and other emerging health and science companies.

Beth Kurth
Vice President, Investor Relations
617 374 8800, x106

And the Winner is…. The Value of Awards

And the Winner is…. The Value of Awards

Did you watch the Academy Awards?  Regardless, I bet you know that Moonlight (eventually) won best picture and Emma Stone won best actress.   While accepting a health science award may not offer the same red carpet experience and drama, the opportunity for recognition is one that should not be overlooked.  As such, we recommend life and health science companies take the time to identify and apply for applicable awards.

Tangible recognition.  Winning an award is a tangible recognition of a company’s expertise.  As such, awards provide independent validation of a company’s credibility and work.   While some awards are initiated by third parties, others are awards for which you can submit on your own behalf.  In either case, an award can provide credibility and visibility in a crowded marketplace. Also, winning an award can be important not just for external audiences, but also for employees, partners and investors.

The award landscape.  There are an array of honors offering different types of recognition for different work. There are awards that recognize commercial success and others that celebrate pre-clinical development work.  There are also awards that celebrate innovation or scientific advancement. While some are general health science industry awards, others focus on categories such as biotech or biopharma.  Important too, some recognize the work of a specific person such as the Chief Scientific Officer.  Some recognize emerging companies, or even companies in emerging markets while other awards recognize market leading research.

Reap the reward.  While some awards are initiated by the grantor, many more require an application by the company.  Therefore implementing a good award program – planning, preparing and applying – can be a valuable addition to your company’s strategic communications program.

Spread the word.  Once you’ve brought home the honor, don’t forget to spread the word.  This includes everything from placement of the award in a prominent location to issuing a press release and ensuring distribution across social media channels.  While you may not get to walk the red carpet, awards can offer a valuable opportunity to extend credibility, raise visibility and ultimately contribute to business success.

LaVoieHealthScience helps advance health and science innovations. We have 16 years’ experience of specialized thinking and delivering strategic communications. Contact us today to learn what we can do for you.

Spotlight: Q&A with Michael Almstetter, CEO, Origenis

Michael Almstetter, CEO
Michael Almstetter, CEO

Q: What does Origenis do?
A: Origenis is creating small molecule drugs capable of penetrating the blood-brain barrier and therefore treating neurodegenerative diseases – commonly known as Central Nervous System, or CNS, diseases. Our technology-based drug design process develops faster, more specific compounds. I am pleased to note our platform has been validated through internal projects and external partners, and has yielded several patented drug candidates now in late stage clinical development since its application in 2005.

Q: What was your inspiration for founding Origenis? What do you hope to achieve?
A: Our goal is to fight neurodegeneration by breaking the vicious cycle that contributes to CNS diseases. That cycle includes microglia activation, which leads to neuro-inflammation, and then cell death, in turn contributing to microglia activation and so on. By inhibiting any of these phases of the cycle, Origenis can help regarding several chronic and acute neurodegenerative diseases such as Parkinson’s Disease, Alzheimer’s, dementia and Multiple Sclerosis as well as Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy.

Q: How does Origenis’ drug discovery platform work?
A: Origenis drug discovery platform has four major pillars: MOREsystem®, MolMind®, and Cippix® represent the proprietary technologies for the fast identification, seamless optimization and efficient synthesis of patentable new chemical entities. The pharmacological efficacy of our compounds is assessed and optimized with BRAINstorm™, the key technology for generating and optimizing brain penetrating compounds at Origenis.

Q: Sounds interesting, is there a competitive advantage?
A: Absolutely! With our leveraging unique chemistry capabilities we provide continual IP-protected new chemical entities. Our unique drug discovery process allows a faster and more specific development of compounds and delivers de-risked new chemical entities for partners, and of course for ourselves. As noted earlier, our platform has been validated not only through internal projects, but also with external partners and has yielded several patented drug candidates.

Q: Can you give us insight into current projects?
A: Origenis develops several, distinct small molecule drugs, which nicely cross the blood brain barrier with no need for a special formulation. These drugs act highly specifically on selected protein kinases responsible for microglia activation, neuronal cell death and neuroinflammation.

Our front-runner is our LRRK2 (Leucine Rich Repeat Kinase 2) therapeutic program. Inhibition of LRRK2 results in a significant decrease in neuronal damage. This opens the avenue for a first disease-modifying treatment in the field of Parkinson’s disease. Our LRRK2 lead drug candidate has outstanding compound properties in terms of potency and selectivity and an execellent brain penetration and PK profle. It should be mentioned that we were the first company to show in-vivo efficacy in an acute neuroegeneration model with our brain available LRRK2 inhibitor.

In addition to the therapeutic programs, Origenis also develops specific PET tracers – necessary tools to translate preclinical compounds into clinical drugs. These PET tracers are a huge strategic advantage in this highly competitive field. Origenis 18F-radiolabelled LRRK2-specific PET tracer, the only one available in the world. This represents the key differentiator in the LRRK2 field and opens a range of partnering and licensing options.

Q: Why is there so much excitement about LRRK2?
A: Two words: science and impact. There is now a deeper understanding of the science and a broader understanding of the impact. In terms of science, a mutation in LRRK2 has been identified as a genetic marker for Parkinson’s disease. In terms of the impact, we have people like Michael J. Fox who has the disease, and Google co-founder Sergey Brin who has the marker. Thus there is more interest from foundations, big pharma and others.

Q: Who else is on the Origenis leadership team?
A: Origenis was founded in 2005 by Michael Thormann, CSO, Andreas Treml, COO and myself. We previously worked together at a multinational biotech company, developing technologies and functioning as a business unit. We have a proven track record in drug design, compound synthesis and characterization. We are based in Munich, Germany and recently added CFO Thomas Loeser who brings financial and deal making expertise, in both Europe and the U.S.

Q: What is Origenis’ business strategy going forward?
A: Since we are already established as an R&D partner of choice, we have a track record of steady and profitable growth of R&D collaborations. That being said, we extended our business model towards faster value creation and are currently seeking up to €20 million for Series A financing to advance our internal pipeline.

We have full ownership of all projects, results and data packages. Our partnering strategy entails out-licensing assets from our significant IP and R&D portfolio and building partnering agreements with large pharmaceutical companies.

So Many Data Slides, So Little Time

So Many Data Slides, So Little Time

We see a lot of scientific data slides – data on animal studies, MOAs, clinical data and more. Alas, with so many data slides, the impact can get subsumed. Audiences are interested in the underlying science or clinical trials, but they’re also interested in the overarching story – what is the problem being solved, why is this an important problem, what expertise does the company bring? With these questions in mind, we offer the following tips for turning data deluge into descriptive data.

Animal Data: Animal data can be compelling, especially for certain indications where there are good animal models. That said, we suggest no more than two showing the data itself, then move on to putting the science in context – the problem being solved and the advantage your company brings.

Mechanism of Action: Our best advice for MOA?  Consider using simple graphics or an animation. Use the fewest data slides you can. Don’t try to tell the audience everything you want them to know. Rather, what is it they cannot forget. Any additional data can go in an optional appendix.

Disease Data: There are two types of disease data: data that defines the scope of the problem being solved, and data that helps explain the nature of the disease being studied. When considering which slides to include in a presentation, first take into account the message to be conveyed – do you need a data slide to define the scope? Maybe an at-a-glance number will do. As to the disease itself, this may best be conveyed with pictures.

Clinical Trials: Clinical trial data is of great interest. The challenge is deciding how much data to present and in which format.  In terms of how much data, we recommend tailoring to the audience. Obviously, if you’re meeting with the head of clinical development from large pharma who is contemplating partnership, more data will be required. But, for other audiences, tailor to their needs. In terms of format, beware the tendency to use too-small, indecipherable graphs. As noted above, focus on what it is that the audience must remember. What do you want to ensure they take away from the clinical trial output.

Data slides are important, but not at the expense of losing the audience in an abundance of scientific statistics. The strategy, mission, plan and people are also important inputs.If you focus on the big picture and ensure data slides are an important element, rather than the reigning role, your company story will be more memorable.

LaVoieHealthScience provides strategic communications, investor relations and public relations to build recognition, increase sales and value for health science innovations. Contact us at to learn more.

How and When to Build a Board: A Primer for Health & Science Emerging Companies

How and When to Build a Board: A Primer for Health & Science Emerging Companies

How many people, when to recruit and what kind of strategy?  It depends. That’s the only answer that applies across all health science emerging companies considering formation of a board.  Board directors serve a variety of roles: they provide strategic decision-making; set operational and performance metrics for the company; provide access to capital; and provide valuable connections.  We surveyed a few trusted board members for advice on when to build a board, how to select board members and what size board to consider.

When to Build a Board.  Deciding when to build a board depends on the stage and goals of the company. Are you raising capital?  Seeking strategic contacts? Venture capital investors will likely get seats and a well-selected strategic advisor may also be a candidate. Of note, smaller companies do not always have the option to hand select members or self-determine timing.  Many times directors are selected based on financing –  they’re selected because they have an equity position, noted John B. Henneman, EVP & CFO, NewLink Genetics, board member for various medical technology companies.

How to Select Board Members.  If you’re a first-time CEO, you might not have the experience. Board members should help build the company, not tell you what you’ve done wrong, commented Chris Adams, Founder, CEO and director, Cydan. Therefore, it is important to have board members that complement the executive management team.  For example, if the CEO has a strong scientific background, it can be constructive to bring on operational expertise.

Number of Board Members.  Seven is an optimal number of board members because any more is too many and you want an odd number.  Boards often have three or four members from venture capital firms which leaves one or two seats for independent directors, according to Steve Hoffman, board member for various biotech companies and Sr. Advisor, PDL BioPharma.  Understanding this limit up front is important when strategizing potential candidates.

Where to find Board Members.  Personal contacts are important in the early stages, but you need to go beyond your network as the company matures, said Robert DeLuccia, former Chairman, Dipexium Pharmaceuticals. Whether it is an in-house recruiter or an external one, they play a vital role in seeking the best candidates with their network of talented and intelligent individuals.

And don’t forget about diversity – a board with a diverse background can be very beneficial in extending the company’s reach.

In sum, corporate governance is an important consideration for all companies, large and small.   Ensuring a responsible board that can help guide corporate direction is important for all parties – management, employees, customers, suppliers, partners and others.  Make sure you make the most of yours.

LaVoieHealthScience helps advance health and science innovations.  We have 16 years’ experience of specialized thinking and delivering strategic communications. Contact us today to learn what we can do for you.



Three Tips to Start the New Year

Three Tips to Start the New Year


Starting the new year off right is important. Here are three tips to keep you on track through 2017:

Strategize for the upcoming year. With so many conferences happening worldwide, this is the time to plan which one(s) are right for your company this year. These are great opportunities to connect with appropriate audiences and learn about the newest and exciting industry news. Choose wisely and make the most of your time once there.

Stay Connected.  You can’t be in person at every event, therefore use social media to stay informed on activities that are happening across the life science ecosystem.  This can be initiating conversations or inserting yourself into ones that are already ongoing. Social media can help you stay plugged in regardless of your geography.

Spend your time efficiently. Whether this is at a conference or in your office, time management is crucial. Your time is important, as is your audience’s. Don’t waste time with a slide deck that drags on and loses effectiveness. Fifteen slides is a perfect amount to get your point across to stakeholders and prospects in the most efficient way.

Interested in starting your new year with a renewed commitment to strategic communications? Contact us at  Learn how we help bring value to our clients’ life science innovations.


Big3Bio Spotlights Q&A with Ian Chan, CEO & Founder, Abpro

abpro logob3b




About Abpro
Abpro is an integrated life science company focused on industrial biochemistry. Through its DiversImmune™ platform, Abpro leverages synthetic biology and immunology to create novel biomolecules for use in research, diagnostics, animal health and therapeutics. Abpro’s platform has been validated by major pharmaceutical, biotechnology and academic labs around the world.

What was your inspiration for founding Abpro?

We wanted to save the time required to generate basic biomolecules, so that life science research can be accelerated so that treatments can be developed faster. We had been end-users of biomolecules before and many times you are just waiting around for several months for biomolecules before research can even be started.


Tell us about Abpro’s proprietary DiversImmune™ Platform.

Historically, generating biomolecules takes a very long time – from months to years. This is because it requires teams of highly skilled scientists working to find the exact conditions to generate each biomolecule one step at a time. The DiversImmune platform replaces the previously labor intensive steps with technology so that the entire process can be accelerated. Traditionally, antibodies can take up to twelve months to make, for example. With our platform, we have been able to reduce this to less than two months. We leverage massively parallel processes so that multiple steps can be run at the same time. We call this process industrial biochemistry because it replaces manual work with the latest technologies in immunology, next-generation sequencing and engineering.

Why do we hear “more shots on goal” with the Abpro platform?

Our platform allows scientists to design new products by allowing the rapid study of genes. Our Diversimmune platform allows the byproducts from the genes to be quickly created and studied so that new products can be created. Our platform creates “more shots on goal” since we are able to very rapidly create the test products that meet targeted endpoints.

What is synthetic biology, sounds like a contradiction in terms?

Synthetic biology is an application of engineering concepts on a broad scale to understand the complex world of biology in a more simple way. It allows biology to be used deliberately to create novel products.

What are the advantages of using Abpro antibodies?

In addition to more shots on goal, our platform creates biomolecules that are similar to the ones create in Nature. For example, in the case of antibodies, these generally have characteristics such as high binding, specificity and functionality. Our biomolecules, especially monoclonal antibodies, are engineered to be as close to the ones you would find in Nature as possible. These natural characteristics make them very appealing since they generally contain fewer side effects compared to artificially-made antibodies. Additionally, our platform is also much faster than competitive approaches.

Who are your current partners? Can you drop some names?

Some of our partners include Amgen, Genzyme, Merck, Pfizer and others. In addition, Abpro has collaborated with several academic research centers, including Harvard University, Massachusetts Institute of Technology and Stanford University and leading academic medical centers to include Massachusetts General Hospital and Brigham and Women’s Hospital.

What do you look for in your partners?

We generally look for partners that are at the forefront of research that have a track record of developing products that have the ability to improve living health, in the research, diagnostics and therapeutics industries. Our partners are global at this point and we are fortunate that they include some of the largest and most successful companies in the industry, such as top academic and research centers and Fortune 100 companies.

You’re often cited as a pioneer in industrial biochemistry. Would you please elaborate?

Industrial biochemistry is the application of synthetic biology and immunology to the life sciences industry so that novel products and treatments can be brought to patients faster. We focus the power of synthetic biology on the life sciences industry.

It sounds like your platform is giving Mother Nature an assist?abpro-ann-liu-l

Immuno-oncology is the fastest-growing category of mAb therapeutics entering clinical studies today and represent tremendous potential. These treatments stimulate Nature’s own immune system to fight cancer.

Immuno-oncology treatments have broad implications for treating disease:

  • We can create molecules that treat disease the way our natural immune system intended to, with better efficacy and lower side effects
  • New therapies can be created that were previously not available against diseases such as cancer

What are some of the goals you hope to achieve at Abpro? Your vision for the future?

Our vision is to be able to help usher in an era powered by biology with novel products that are developed faster and can benefit mankind. Biology is relevant in all aspects of society. By being able to understand biology faster, we can design new products and bring them to market in an accelerated manner. This includes treating disease, such as cancer, at a new level with cutting edge products.

Any final words?

We are excited about the current trends using antibodies to treat disease. There is real progress being made to help patients. We look forward to continuing to play a major role in the industry and helping our partners not only accelerate their research but to bring novel products that can improve living health to market.


Life Science Leader Features Stefan Weber, CEO of Newron Pharmaceuticals SpA, on Drug Company Discovery & Commercialization



Drug Company Discovery & Commercialization: An Election Year Analogy

stefanweberBy Stefan Weber, CEO and Executive Director, Newron Pharmaceuticals SpA

When smaller, boutique drug companies move from precommercial discovery to postcommercial marketing, they can experience a shock. Precommercial work is typically rigorous and controlled with trials conducted in sequential fashion and oversight done by recognized governing bodies. Of course there can be detours along the way, but generally speaking, the path itself is well-known. In contrast, postcommercial work expands the ecosystem and, therefore, brings with it an increasing number of participants, functions, relationships, and unknowns.

To continue reading this story, subscribe to Life Science Leader.



LaVoieHealthScience Honored with Bell Ringer Award for Healthcare Publicity Campaign


Campaign featured signature event, digital content and media relations

BOSTON, MA – June 10, 2016 – LaVoieHealthScience (LHS), an integrated strategic communications agency that is focused on health and life science, announced today it has won a Bell Ringer Merit Award in the healthcare publicity category from the Publicity Club of New England for the agency’s work on behalf of its client, Hydra Biosciences, a biopharmaceutical company focused on the development of novel drugs to treat pain, inflammation, anxiety, and other diseases using its expertise in novel ion channels.

LaVoieHealthScience developed a multi-faceted awareness campaign to highlight the need for better alternatives to opioids for treating pain that would improve efficacy and side effect profiles.  Hydra Biosciences is the world leader in the field of Transient Receptor Potential (TRP) ion channels and is developing medicines that offer improved outcomes with minimal side effects for people with serious diseases and conditions.

The campaign included a signature event called PAIN: a conversation with highly-regarded speakers, digital content, advocacy group outreach, and media relations.  The event drew a standing-room crowd, including several leaders and advocacy groups, to a premier Boston hotel for a networking reception and panel.

“I want to thank our talented team and our client, Hydra Biosciences for their creativity and execution on this important awareness program.  We are honored to be recognized again in 2016 by the Publicity Club of New England,” stated Donna L. LaVoie. “Hydra Biosciences is a great company with leading technology in TRP modulation.  Their commitment to sound science is grounded by an ethical approach to the business of science with the patient in mind.”

Russell Herndon, President and CEO of Hydra Biosciences added, “Our science targets the same cellular pathways that other pain medications do but instead of acting in the brain, like opioids, our compounds work by blocking the pain signals directly in the area where the pain is occurring.  This initiative was  focused on identifying the need for innovation in the treatment of chronic pain while building the support and investment into research and development efforts focused on finding new solutions to this epidemic.  We are honored to receive the recognition for this program with our PR partner, LaVoieHealthScience.”

Since 1969, the Publicity Club of New England’s Bell Ringer Awards have been a symbol of outstanding achievement for New England public relations and communications professionals in every field and industry and across all forms of media.

About LaVoieHealthScience
LaVoieHealthScience partners with leading life science brands to build value for their companies, attract capital, and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received 28 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients.


Beth Kurth
Vice President, Investor Relations
(617) 374-8800 ext. 106

Donna LaVoie Delivers Workshop at BIO International on The LHS 15-Slide Presentation™

Donna LaVoie Delivers Workshop at BIO International on The LHS 15-Slide Presentation™


Boston – June 10, 2016 – Donna LaVoie, president and CEO of LaVoieHealthScience (LHS), an award winning integrated strategic communications agency focused on health and life science, delivered a workshop on how to create an essential company presentation in just 15 slides in front of a packed room at this week’s BIO International Conference in San Francisco. Donna also reviewed the basics of creating an elevator pitch.

“Communication is an art acquired only from years of learning and practice, and I was thrilled to be selected by BIO to lead this important workshop on a process that drives a company’s key messages to engage stakeholders and achieve company goals,” said Donna LaVoie. “Being a great scientist or a great business visionary is just not enough; you must also be a great communicator to succeed in business today.”

Last month LHS was issued a U.S. Service Mark for The LHS Fifteen-Slide Presentation™, which designates a clear outline for life science companies to explain their product category, market differentiator, leadership position, regulatory pathway and financial position. The presentation is designed for use across audiences, including prospective partners, employees, investors and others. The 15 slides ensure key information is covered in a logical, digestible presentation. Starting with this structured approach, LHS uses the methodology to optimize credibility, visibility and opportunity for its client companies.

LaVoieHealthScience has developed a thought leadership series of videos and whitepapers on public speaking covering The LHS 15-Slide Presentation™, Public Speaking Strategies for the CEO and Creating Your Elevator Pitch. More information on this series can be found here.

About LaVoieHealthScience
LaVoieHealthScience partners with leading life science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received 27 awards over the past six years in recognition of the work it has done for its industry-leading clients. The agency maintains a comprehensive list of investor, partnering and medical conferences which can be found here.

LaVoieHealthScience is ranked by O’Dwyer’s PR as one of the Top 30 Independent Healthcare PR firms in the US.


Beth Kurth
Vice President, Investor Relations
617-374-8800 x106